The effect of intermittent fasting on muscle mass in overweight, middle-aged me

Not Applicable

Completed

• Conditions: Obesity; Sarcopenia; Diet and Nutrition - Obesity; Musculoskeletal - Normal musculoskeletal and cartilage development and function

• Registration Number: ACTRN12619000757112
• Lead Sponsor: Australian Catholic University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-05-22
• Study Completion: 2020-03-16
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 37

Inclusion Criteria

Male
- Age: 35-55 years
- BMI: 25-35 kg/m2

Exclusion Criteria

1)Current diagnosis of Type 2 Diabetes (HbA1C >6.5% or 48 mmol/mol)
2)Unable to attend the laboratory for visits and adhere to the 3-day lead-in diet and 10-day intervention diet
3)Currently meeting physical activity guidelines (i.e. doing more than 150 min of physical activity per week or >10,000 steps per day)
4)Major or chronic illness that impairs mobility or eating/digestion;
5)Previous bariatric surgery;
6)Shift workers;
7)Smoker (cigarette, e-cigarette or marijuana);
8)Individuals with strict dietary intake regimes (i.e. vegan, avoidance of principal study foods);
9)Individuals who are currently restricting their dietary intake (i.e. actively trying to diet and lose weight) or participating in regular fasting (defined as fasting >16 h/day or having completed twelve 24-h fasts within the past year);
10)Participating in shift work (i.e. >3 h between 22:00 h and 05:00 h for 1 day per week (>50 days per year))
11)Not weight stable (>5 kg body weight change over last 3 months);
12)Individuals who do not consume breakfast on at least 5 of 7 days per week (i.e. not eating regular meals);
13)On prescribed medications required to be taken with food in the early morning or late evening or taking other prescribed medications for <3 months.
14)On prescribed anti coagulation medications (interfering with muscle biopsy procedures)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome measurement will be muscle protein synthesis rates (%/day) measured using the rate of labelled water (D2O) uptake from the muscle biopsy samples and alanine enrichments in saliva. [Day 0 and Day 11]